Roche’s Enspryng gets FDA Priority Review for MOGAD after 68% reduction in relapse risk
Roche has secured FDA Priority Review for Enspryng in myelin oligodendrocyte glycoprotein antibody-associated disease after Phase 3 data showed a 68% reduction in relapse risk versus placebo.